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Summary Praziquantel is efficacious against the adult stages of all human schisto-
some parasites, and has become the drug of choice for morbidity control of schisto-
somiasis. There is concern that resistance to praziquantel might develop or already
exists, and could be further facilitated through new control initiatives relying on
large-scale administration of praziquantel. Therefore, monitoring praziquantel effi-
cacy in different epidemiological settings is required. We assessed the efficacy and
side effects of praziquantel against Schistosomamansoni in a rural community of west-
ern Côte d’Ivoire. Three consecutive stool specimens from 545 children and adults
were examined by the Kato-Katz technique, revealing an overall prevalence of 40.9%.
S. mansoni-infected individuals were treated with a single oral dose of praziquantel
at 40mg/kg. The most frequent side effects were abdominal pain, dizziness and diar-
rhoea. The overall cure rate, assessed 6 weeks post-treatment, was 60.9%. Moderate
or heavy infections were only cleared in half or one-third of the individuals, respec-
tively. The total egg count reduction was 61.4%. Infection intensity pre-treatment
was significantly associated with age, cure rate, reported diarrhoea and dizziness.
Our findings call for additional studies that rigorously evaluate the efficacy of prazi-
quantel against different schistosome species in entire communities, using similarly
sensitive diagnostic approaches as employed here.
© 2003 Royal Society of Tropical Medicine and Hygiene. Published by Elsevier Ltd. All
rights reserved.
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1. Introduction
Praziquantel is the current drug of choice for the
treatment and morbidity control of schistosomia-
sis. Its efficacy against all five species of human
schistosomes, good tolerability, ease of adminis-
tration, and substantial price reduction (average
cost for adult treatment in 2003 is US$ 0.30) are
key features explaining the success of this drug
(Bergquist, 2002; Doenhoff et al., 2002; Fenwick
et al., 2003). Using the recommended dosages,
cure rates recorded in a 1984 review were: 75—
85% for Schistosoma haematobium, 63—85% for S.
mansoni, and 60—80% for mixed infections with
S. mansoni and S. haematobium (Wegner, 1984).
More recent studies found cure rates of 60—90%
for S. mansoni in different epidemiological settings
(Davis, 1993; Gryseels et al., 1987; Kumar and
Gryseels, 1994; Utzinger et al., 2000a). However,
in an intensive focus in northern Senegal, the drug
resulted in very low cure rates, namely 18—39%
(for recent reviews see Danso-Appiah and De Vlas,
2002; Gryseels et al., 2001). Side effects due to
praziquantel usually occur in a relatively large pro-
portion of patients (30—60%), but they are mild and
transient and disappear within 24 h (Berhe et al.,
1999; Cioli and Pica-Mattoccia, 2003; Jaoko et al.,
1996; N’Goran et al., 2003).
The major weaknesses of praziquantel are its
lack of efficacy against immature parasites (Sabah
et al., 1986; Xiao et al., 1985), and the risk of
resistance development (Danso-Appiah and De
Vlas, 2002). The stage-specific efficacy of prazi-
quantel is thought to be the likely source of most
treatment ‘failures’ experienced in clinical prac-
tice (Cioli and Pica-Mattoccia, 2003). In areas
of intense transmission people are likely to be
infected simultaneously with different develop-
mental stages of the parasite. Two praziquantel
treatments, given a few weeks apart, showed
promising results with elevated cure rates and egg
count reductions (N’Goran et al., 2003; Picquet
et al., 1998; Renganathan and Cioli, 1998; Utzinger
et al., 2000a). Another potentially interesting ap-
proach is combination chemotherapy with praz-
iquantel and an artemisinin derivative, because
these compounds are complementary with regard to
their stage-specific susceptibilities (Utzinger et al.,
2003).
According to the overall endemicity of schisto-
somiasis in a given setting, WHO currently rec-
ommends either selected treatment of infected
individuals or systematic praziquantel adminis-
tration (WHO, 2002). However, the prospect of
relying on a single drug for a disease affect-
ing 200 million people is an alarming situation
(Cioli, 2000). In addition, it is anticipated that
praziquantel usage will increase with the recent
launch of the ‘Schistosomiasis Control Initiative’
(http://www.schisto.org), and the deworming and
school-feeding programmes of the World Food
Programme, the World Bank and WHO, already
operating in 19 of the 41 endemic African coun-
tries (Fenwick et al., 2003; Savioli et al., 2002).
Consequently, monitoring the efficacy of prazi-
quantel in different epidemiological settings is a
high priority (Renganathan and Cioli, 1998) and has
to be built into operational programmes (WHO,
1999).
Recently, an attempt to interpret low S. mansoni
cure rates from Senegal on the basis of trends from
other studies was carried forward (Danso-Appiah
and De Vlas, 2002). The authors identified 11 stud-
ies that met the following inclusion criteria: (1)
studies involved entire communities or representa-
tive sub-samples thereof; (2) participants received
a single oral dose of 40mg/kg praziquantel; (3)
treatment outcomes were expressed as a cure rate;
and (4) praziquantel efficacy was assessed between
1 and 12 months post-treatment. The authors con-
cluded that even if high pre-treatment intensities
of infection could partly explain low cure rates,
the suspicion about tolerance or resistance to praz-
iquantel could not be ruled out for Senegal. The
limited number of studies and the fact that they
all employed slightly different designs and diagnos-
tic procedures, call for additional studies in other
settings.
This paper reports the first evaluation of the
efficacy and side effects of praziquantel against
S. mansoni in an entire community of Côte d’Ivoire.
A sensitive diagnostic approach was employed by
quantitative examination of 3 consecutive stool
specimens per individual prior and after prazi-
quantel administration. The study estimates cure
rates and egg count reductions, and assesses side
effects after treatment, placing special empha-
sis on associations to pre-treatment infection
intensities.
2. Materials and methods
2.1. Study area, population and consent
The study was carried out in Zouatta II, a village sit-
uated in the district of Man in western Côte d’Ivoire.
This area has been reported to be a major focus of
S. mansoni several decades ago (Service des
Grandes Endémies, 1970; cited in Doumenge et al.,
1987). This has been confirmed by a recent,
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large-scale, cross-sectional survey, when examina-
tion of >5000 schoolchildren revealed an infection
prevalence of S. mansoni of 54% (Utzinger et al.,
2000b).
The study was launched in May 2002. First, the
village chief was asked for permission to work
in Zouatta II, and then a meeting was organized
with the village authorities to explain the aims
and procedures of the study. After consent was
obtained and the village chief had designated 8
persons to assist our research team, the village
authorities informed the community. A detailed
demographic survey was carried out in 75 house-
holds, randomly selected among the estimated
100—120 households, according to the EPI survey
approach (Lemeshow and Robinson, 1985). For
each household, the number of inhabitants was
recorded and the geographic coordinates were
collected using a hand-held GPS (Magellan 320).
For each individual, the name, sex and age were
recorded. Identification numbers were then as-
signed to each household, as well as each partici-
pant. Two researchers specialized in the fields of
sociology (C.A. Adjoua) and socio-geography and
visual communication (A. Luginbühl), together with
the 8 local assistants, conducted a questionnaire
survey, both at the household and the individual
level. Pre-tested questionnaires were utilized for
appraisal of socio-economic factors, perceived
morbidity indicators and health-seeking behaviour
patterns.
Subsequently, a detailed parasitological survey
was carried out. Due to logistic reasons and the ca-
pacity of our laboratory technicians to process a
maximum of 300 stool and 300 urine specimens per
day, the selected households were geographically
split into 2 similarly large groups. In the evening
before the first parasitological survey commenced,
the study participants reassembled at the village
chief’s domicile and the procedures of the forth-
coming survey and subsequent treatments were ex-
plained.
2.2. Field and laboratory procedures
The 8 people assisting our research team went
from one household to another and distributed
pre-packed plastic bags containing stool and urine
containers, marked with the name and identifica-
tion number of each participant in group 1. The
household chiefs were asked to return the con-
tainers early in the next morning, filled with small
amounts of fresh stool and urine specimens, to a
central location in the village. In cases where the
household head was unable to return the filled con-
tainers, another member of the same household
could fulfil this task. This procedure was repeated
over 3 consecutive days. It allowed study partici-
pants to go to work in the fields or attend school
during survey days. On the third day, all study par-
ticipants of group 1 were also invited for a full clin-
ical examination and to provide finger prick blood
samples for thick and thin blood films. Thereafter,
treatment against S. mansoni and soil-transmitted
helminths or other ailments, was administered.
Group 2 was enrolled from day 5 onwards, adhering
to the same field procedures. These activities were
completed on day 7 by a full clinical examination,
investigation of malaria parasites, and subsequent
drug administration.
Stool, urine and blood specimens were brought
to the central laboratory in Man. The stool spec-
imens were processed as follows. First, a 1—2 g
portion of each specimen was preserved in 10ml
sodium acetate—acetic acid—formalin (SAF). Sec-
ond, a single Kato-Katz thick smear was prepared
from each specimen, using 42mg plastic templates
(Katz et al., 1972). After a clearing time of 30—
45min, the Kato-Katz thick smears were examined
by light microscopy, and eggs of S. mansoni, hook-
worms, Ascaris lumbricoides and Trichuris trichiura
were recorded by 4 experienced microscopists. For
quality control, 10% of the slides were randomly se-
lected at the end of each day and re-examined by
the senior microscopist.
The SAF-conserved stool samples were forwarded
to a reference laboratory in Switzerland for ap-
praisal of intestinal protozoa. Urine specimens were
tested with reagent strips (Nephur 6—Test®, Roche
Diagnostics, Mannheim, Germany), and 3—4ml of
urine were frozen and forwarded to a reference lab-
oratory in the UK for NMR-based metabonomic anal-
yses. Thick and thin blood films were stained with
Giemsa and species-specific densities of Plasmodia
were estimated under a microscope, following stan-
dardized, quality-controlled procedures. These re-
sults will be presented elsewhere.
2.3. Chemotherapy, reported side effects
and follow-up
After the last stool specimens had been obtained
from study participants in group 1 (day 3) and group
2 (day 7), all individuals who had resulted positive
for S. mansoni were invited for praziquantel treat-
ment at a single oral dose of 40mg/kg. Individuals
who were S. mansoni-negative but had an infec-
tion with soil-transmitted helminths (hookworms,
A. lumbricoides or T. trichiura) were treated with
albendazole (400mg). Adults who were infected
neither with S. mansoni nor any soil-transmitted
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helminth received vitamins. When the full clinical
examination by the study physician revealed other
diseases/conditions, the patients were referred for
treatment to the central laboratory in the town of
Man.
Individuals treated with praziquantel were
instructed to report side effects within 24 h
post-treatment. The list of symptoms included nau-
sea, vomiting, abdominal pain, diarrhoea, itching,
headache, urticaria and dizziness. Six weeks later
a follow-up survey was carried out among these
individuals. Stool specimens were again collected
over 3 consecutive days and Kato-Katz thick smears
were quantitatively examined. Individuals who con-
tinued to excrete S. mansoni eggs in their faeces
were treated with another dose of praziquantel,
also administered at 40mg/kg.
2.4. Data management and statistical
analyses
Data were double entered and cross-checked using
EpiInfo (version 6.04, Centers for Disease Control
and Prevention, Atlanta, GA, USA). Analyses were
performed with STATA (version 7.0, Stata Corpo-
ration, College Station, TX, USA). Praziquantel
efficacy was calculated for those study partici-
pants who had at least 2 Kato-Katz thick smears
examined pre- and post-treatment and were ad-
ministered praziquantel. To estimate the mean
S. mansoni egg counts of each individual, the arith-
metic means were calculated both at the baseline
and follow-up surveys. These arithmetic means de-
termined the infection intensity of each individual
and were utilized to calculate geometric means
for the population. Infection intensities were sub-
divided into 3 categories as follows: (1) light in-
fection: 1—100 eggs/g of stool (epg); (2) moderate
infection: 101—400 epg; and (3) heavy infection:
>400 epg (WHO, 2002). Age was subdivided into
5 categories: <10 years; 10—14 years; 15—24 years;
25—39 years; and ≥40 years. The parasitological
cure rate was calculated as the proportion of in-
dividuals who had S. mansoni eggs in their stool
prior to praziquantel administration and those who
excreted no eggs after treatment. Egg count re-
duction was calculated as [1 - (geometric mean epg
after treatment/geometric mean epg before treat-
ment)] multiplied by a factor 100. The groups were
compared with the 2-test, Fisher’s exact test and
Mann-Whitney statistics, including 95% confidence
intervals (CI) of means. Side effects were analysed
by examining separately each one of the 8 spe-
cific side effects in relation to S. mansoni infection
intensity.
3. Results
3.1. Operational results and study
compliance
In May 2002, data pertaining to demographic,
socio-economic, perceived morbidity indicators,
infection risk- and health seeking behaviour pat-
terns were collected from all inhabitants of 75
randomly selected households in Zouatta II. During
the cross-sectional parasitological baseline survey,
561 individuals participated. The large majority,
namely 545 (97.1%), provided at least 2 stool spec-
imens, hence they were considered for detailed
analyses (Fig. 1). The numbers of male and female
participants were similar (ratio = 1.04; χ2 = 0.49,
P = 0.70). Participants’ ages ranged from 5 days to
91 years, consisting of: <10 years, n = 184 (33.8%);
10—14 years, n = 74 (13.6%); 15—24 years, n = 75
(13.8%); 25—39 years, n = 101 (18.5%); and ≥40
years, n = 111 (20.4%). Children aged 10—14 years
consisted of twice as many boys as girls (50 versus
24), whereas in older age categories there were
slightly more women than men. This resulted in a
n = 561 
Individuals present in Zouatta II 
during baseline survey
n = 545 
Individuals with > 2 Kato-Katz 
thick smears 
n = 161 
thick smears at follow-up 
n = 63 
Individuals remained 
S. mansoni positive 
n = 98 
Individuals became 
S. mansoni negative 
n = 223 
Individuals positive for 
S. mansoni 
n = 200 
Individuals treated with a single oral 
dose of praziquantel (40 mg/kg)
Individuals with > 2 Kato-Katz 
Fig. 1 Study compliance for assessment of efficacy and
side effects of praziquantel against Schistosoma mansoni
in the village of Zouatta II, western Côte d’Ivoire.
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Table 1 Number (%) of study participants with Schistosoma mansoni infections at different intensity levels and
geometric mean egg count for the population before the administration of praziquantel in the village of Zouatta
II, western Côte d’Ivoire (n = 545)
S. mansoni infection level (eggs/gram stool)a Cumulative results: no. of individuals (%)
After sample 1 After sample 2 After sample 3b
Light infection (1—100) 74 (13.6) 123 (22.6) 145 (26.6)
Moderate infection (101—400) 36 (6.6) 49 (9.0) 57 (10.4)
Heavy infection (>400) 27 (4.9) 25 (4.6) 21 (3.9)
All infections (>0) 137 (25.1) 197 (36.2) 223 (40.9)
Geometric mean egg count (95% CI) 122 (98—152) 69 (57—83) 57 (47—69)
a For stratification into different infection intensity levels, after collection of 2 or 3 samples, arithmetic means
were used to establish the mean egg count of each individual.
b 98 of 545 individuals provided 2 instead of 3 stool specimens.
significant effect of the association between age
categories and sex (χ2 = 9.88, d.f. = 4, P = 0.04).
The mean age between the 2 sexes was not signifi-
cantly different (men = 22.4 years, women = 23.7
years; Mann-Whitney z = −0.81, P = 0.42).
3.2. S. mansoni infection before
praziquantel treatment
Table 1 shows the prevalence, infection intensity
and geometric mean egg counts of S. mansoni
among the 545 study participants before the ad-
ministration of praziquantel after sample 1, sample
2 and sample 3. Examination of the first Kato-Katz
thick smear revealed eggs of S. mansoni in 137
participants equal to an observed prevalence of
25.1%. The prevalence of infection was as high
as 40.9% after the examination of 3 consecutive
Kato-Katz thick smears. A considerable number of
patients displaying light infections, but to some
degree also moderate infections, were missed by
Table 2 Baseline characteristics of Schistosoma mansoni infections among 545 study participants from the village
of Zouatta II in western Côte d’Ivoire with regard to sex and age
Indicator Infection intensity 2 P-value
None infected Light Moderate Heavy
Sex
Male 160 75 31 12
Female 162 70 26 9 0.83 0.84
Age (years)
<10 159 22 2 1
10—14 43 22 6 3
15—24 17 36 19 3
25—39 49 28 16 8
≥40 54 37 14 6 119.29 <0.001
a single Kato-Katz thick smear. In contrast, heavy
infections were all detected after the first stool
examination. After the maximum sampling effort
of 3 Kato-Katz thick smears, 26.6% of the study par-
ticipants displayed light, 10.4% moderate and 3.9%
heavy infections. The geometric mean egg count
among all those individuals who were S. mansoni
positive was 57 epg (95% CI: 47—69).
There was no significant association between
level of infection intensity and sex (χ2 = 0.83,
d.f. = 3, P = 0.84; Table 2). On the other hand,
the association between level of infection inten-
sity and age categories was highly significant with
the age group of 15—24 years exhibiting the high-
est infection intensity (χ2 = 119.29, d.f. = 12,
P < 0.001; Fig. 2). Consequently, further analyses
were performed for the 5 different age categories.
The observed prevalences of hookworm, T.
trichiura and A. lumbricoides, following examina-
tion of 3 Kato-Katz thick smears, were 36.1%, 5.3%
and 1.7%, respectively.
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Table 3 Number (%) of study participants with Schistosoma mansoni infections at different intensity levels and
geometric mean egg count for the population 6 weeks after praziquantel treatment (single oral dose of 40mg/kg)
among 161 people
S. mansoni infection level (eggs/gram stool)a Cumulative results: no. of individuals (%)
After sample 1 After sample 2 After sample 3b
Light infection (1—100) 13 (8.1) 35 (21.7) 56 (34.8)
Moderate infection (101—400) 5 (3.1) 7 (4.4) 5 (3.1)
Heavy infection (>400) 2 (1.2) 1 (0.6) 2 (1.2)
All infections (>0) 20 (12.4) 43 (26.7) 63 (39.1)
Geometric mean egg count (95% CI) 64 (37—112) 33 (23—48) 22 (16—30)
a For stratification into different infection intensity levels, after collection of 2 or 3 samples, arithmetic means
were used to establish the mean egg count of each individual.
b 23 of 161 individuals provided 2 instead of 3 stool specimens.
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Fig. 2 Age-prevalence curve of Schistosoma mansoni
infections () and age-cure rate curve () following a
single oral dose of 40mg/kg praziquantel (vertical bars
indicate 95% confidence intervals).
3.3. Effect of praziquantel and
parasitological cure rate
From those 223 participants found with S. man-
soni eggs during the baseline survey, 200 (89.7%)
were treated with a single oral dose of 40mg/kg
praziquantel. The remaining 23 individuals missed
treatment, because they were travelling, preferred
Table 4 Effect of single oral dose of 40mg/kg praziquantel administered to 161 S. mansoni-infected patients in
Zouatta II, western Côte d’Ivoire in relation to infection intensity pre-treatment
S. mansoni infection level
pre-treatment (eggs/gram
stool)
No. of
patients
treated
No. of
patients
cured (%)
No. of patients non-cured
Light
infection
Moderate
infection
Heavy
infection
All
infections
Light infection (1—100) 101 71 (70.3) 27 2 1 30
Moderate infection (101—400) 42 21 (50.0) 18 3 0 21
Heavy infection (>400) 18 6 (33.3) 11 0 1 12
All infections (>0) 161 98 (60.9) 56 5 2 63
to work or refused to take the drugs. Six weeks
later, 161 participants provided at least 2 stool
specimens, hence this cohort was utilized for es-
timation of the parasitological cure rate. Table 3
summarizes the prevalence, infection intensity and
geometric mean egg counts among this cohort after
examination of sample 1, sample 2 and sample 3.
The observed prevalence after examination of the
first Kato-Katz thick smear was 12.4%. It increased
3-fold, reaching an overall prevalence of 39.1% af-
ter 3 Kato-Katz thick smears had been examined.
This translates to an overall cure rate of 60.9%. Had
only the first Kato-Katz thick smear been examined,
the cure rate would result in 87.6%, and hence
would have been significantly overestimated. The
geometric mean egg count among egg positive in-
dividuals was 22 epg (95% CI: 16—30), resulting in
a total egg count reduction of 61.4%. There were
still 7 individuals displaying either moderate or
heavy infections. The overall cure rates among
individuals who had light, moderate or heavy in-
fections pre-treatment were 70.3%, 50.0% and
33.3%, respectively (Table 4). Consequently, there
was a significant association between cure rates
and level of infection intensities prior to treat-
ment (χ2 = 11.58, d.f. = 2, P = 0.003), but cure
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Table 5 Parasitological cure rate after praziquantel
treatment in relation to sex and age
Indicator No. of
patients
infected
No. of
patients
cured (%)
2 P-value
Sex
Male 90 56 (62.2)
Female 71 42 (59.2) 0.16 0.69
Age
<10 15 12 (80.0)
10—14 27 16 (59.3)
15—24 30 15 (50.0)
25—39 42 23 (54.8)
≥40 47 32 (68.1) 5.51 0.24
rates were independent of sex and age categories
(Table 5).
As shown in Table 4, most of the moderate and
heavy S. mansoni infections were either cleared
or reversed to light infections after praziquantel
treatment with 4 exceptions. First, 1 heavy infec-
tion (mean egg count prior to treatment 3920 epg)
remained heavy, although with a sharp reduction in
mean egg counts (928 epg post—treatment). Sec-
ond, 3 moderate infections remained moderate.
Third, there were 2 individuals with light infec-
tions pre-treatment who were found with moder-
ate infections post-treatment (mean egg counts
changed from 32 and 24 epg pre-treatment to 208
and 304 epg post-treatment, respectively). Fourth,
1 light infection pre-treatment was diagnosed as a
heavy infection post-treatment (mean egg counts
were 36 and 1008 epg pre- and post-treatment,
respectively).
Table 6 Number (%) of reported side effects among those 25 individuals (out of the total of 200 treated individuals)
who complained of 1 or more side effects within 24 h after praziquantel administration in relation to Schistosoma
mansoni infection intensity pre-treatment
Reported side effects Infection intensity pre-treatment Total records 2 P-value
Light (n = 128) Moderate (n = 53) Heavy (n = 19)
Abdominal pain 6 (4.7) 3 (5.7) 3 (15.8) 12 0.13*
Dizziness 4 (3.1) 5 (9.4) 3 (15.8) 12 0.04*
Diarrhoea 4 (3.1) 0 4 (21.1) 8 16.85 <0.001
Itching 2 (1.6) 2 (3.8) 1 (5.3) 5 0.35*
Vomiting 1 (0.8) 0 1 (5.3) 2 4.09 0.13
Headache 1 (0.8) 1 (1.9) 0 2 0.59*
Nausea 1 (0.8) 1 (1.9) 0 2 0.59*
Urticaria 1 (0.8) 0 0 1 0.57 0.75
Total 20 12 12 44
* P-value was based on Fisher’s exact test.
3.4. Side effects
Among the 200 treated individuals, 25 (12.5%)
reported 1 or more side effects within 24 h
post-treatment (Table 6). A significantly higher
proportion of individuals with high infection inten-
sities reported diarrhoea (χ2 = 16.85, d.f. = 2,
P < 0.001) and dizziness (Fisher’s exact test, P =
0.036) when compared to individuals with light or
moderate infections. None of the other side effects
showed an association with infection intensity,
and side effects showed no association with age
categories. Abdominal pain was the only reported
side effect that was significantly associated with
sex (women 9 cases vs. men 3 cases, χ2 = 4.02,
P = 0.045).
4. Discussion
The parasitological cure rate of 60.9% following
the administration of a single oral dose of 40mg/kg
praziquantel to S. mansoni-infected individuals
from western Côte d’Ivoire was at the bottom end
of the usually reported cure rates of 60—90% in
different epidemiological settings, using the same
antischistosomal drug against this schistosome
species (Davis, 1993; Kumar and Gryseels, 1994;
Utzinger et al., 2000a). However, markedly lower
cure rates of only 18—39% were observed in a re-
cent and very intense focus of S. mansoni in north-
ern Senegal. After in-depth analysis of these data
several explanations were offered to interpret the
unexpectedly low cure rates (Danso-Appiah and De
Vlas, 2002; Gryseels et al., 2001). In the study pre-
sented here the overall egg count reduction was
also low (61.4%): this is considerably lower than
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the normally reported egg count reductions of over
80% or 90% (Gryseels et al., 1987; Utzinger et al.,
2000a). It was even lower than in Senegal where 2
different studies revealed egg count reductions of
71% (Picquet et al., 1998) and 86% (Stelma et al.,
1995). Recent work employing a 2-treatment pro-
tocol against S. mansoni in Senegal resulted in a
cure rate of 76% and egg count reduction of 88%
(Picquet et al., 1998). These findings indicated that
intense disease transmission is an important factor
explaining, at least partially, the apparent lack of
praziquantel efficacy in the Senegal focus (Kusel
and Hagan, 1999). Other studies drew the same
conclusions although they remained short on quan-
tification (for a review see Danso-Appiah and De
Vlas, 2002). Pre-patent infections may also account
for some of the ‘treatment failures’, since juvenile
stages of S. mansoni are largely insensitive to praz-
iquantel (Sabah et al., 1986; Xiao et al., 1985). The
design of the present study did not allow quantifi-
cation of the extent of pre-patent infections.
Concurrent infections with other parasites and
host-related factors have also been found to influ-
ence cure rates and egg count reductions. A study
in Senegal, investigated different host-related fac-
tors between those persons who were cured and
those who remained S. mansoni egg-positive de-
spite treatment (van Lieshout et al., 1999). Inter-
estingly, age and pre-treatment infection intensi-
ties were the only 2 factors that were significantly
associated with low cure rates, while humoral im-
mune responses showed no apparent association.
Other studies also demonstrated that cure rates
depend on infection intensities prior to praziquan-
tel chemotherapy. These findings are consistent
both for S. mansoni and S. haematobium (Andrews,
1981; Berhe et al., 1999; N’Goran et al., 2003;
Picquet et al., 1998; Stelma et al., 1995; Utzinger
et al., 2000a). Our study adds to this body of evi-
dence, as there was also a highly significant associ-
ation between S. mansoni infection intensity prior
to treatment and cure rates. While heavy infections
(>400 epg) showed a low cure rate of only 33.3%,
light infections were cleared in 70.3% of the cases.
Comparably low cure rates of 42.9% among heavy
infections (401—1000 epg) were found by Picquet
et al. (1998) in Senegal after the initial praziquan-
tel treatment. The overall cure rate in this group
increased to 86% after the second praziquantel
treatment. Infections with more than 1000 epg
resulted in cure rates of 27% and 78% after the
first and second round of treatment, respectively.
Consequently, administration of 2 doses of prazi-
quantel within a few weeks was proposed for the
treatment of heavy infections in this setting. This
approach also showed success against S. haemato-
bium in a highly endemic area of Côte d’Ivoire with
an overall cure rate of 93% after two praziquantel
treatments (N’Goran et al., 2003).
The peak in S. mansoni prevalence was observed
in the age group of 15—24 years, which is consis-
tent with previous studies where the overall preva-
lence and intensity of infection were relatively low
(Fulford et al., 1992). The evidence suggests that
in populations where the level of infection is high,
immunity will be acquired more rapidly, and conse-
quently the peak prevalence will occur at younger
age. In contrast, immunity will be acquired later
when levels of infections are low and consequently
the peak will be expected in older ages (Anderson
and May, 1985; Woolhouse, 1998).
In most community-based studies, cure rates
have been estimated on the basis of only 1 or 2
Kato-Katz readings, usually derived from single
stool specimens (Danso-Appiah and De Vlas, 2002;
Gryseels et al., 2001). Our study is based on ex-
amination of 3 Kato-Katz thick smears derived
from consecutive stool specimens, both prior and
after praziquantel administration, to overcome
the inherent problem of day-to-day variation in S.
mansoni egg outputs (Barreto et al., 1990; De Vlas
and Gryseels, 1992; De Vlas et al., 1992; Engels
et al., 1996; Utzinger et al., 2001). In our previ-
ous work carried out in a neighbouring village we
showed that examination of at least 3 consecutive
Kato-Katz thick smears results in a high diagnostic
sensitivity (Utzinger et al., 1998). Examination of
multiple stool specimens is of particular relevance
after implementation of chemotherapeutic inter-
ventions, when the overall geometric mean egg
count is likely to be low. The present study reiter-
ates that adherence to such sensitive diagnoses is
mandatory for estimation of ‘true’ cure rates (De
Vlas and Gryseels, 1992; Doenhoff, 1998; Utzinger
et al., 2000a). The apparent cure rate after exam-
ination of single stool specimens before and after
praziquantel administration was 87.6%, whereas
the ‘true’ cure rate was only 60.9%. Several authors
emphasised the lack of uniform methodologies
when assessing praziquantel efficacies and imply
the need to standardize treatment and evaluation
protocols, so that findings can be readily compared
between different settings, facilitating the inter-
pretation of cure rates and in turn elucidating the
potential development of resistance to praziquan-
tel (Danso-Appiah and De Vlas, 2002; Geerts and
Gryseels, 2000; Utzinger et al., 2001).
Side effects due to praziquantel were mild and
transient, i.e. they occurred in the first hours after
treatment and gradually resolved within 24 h. They
were consistent with those side effects reported
in other schistosome-endemic areas. Abdominal
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pain and dizziness were the most prominent side
effects, followed by diarrhoea. Among these both
diarrhoea and dizziness showed significant associa-
tions with pre-treatment infection intensities. Pre-
vious studies also found higher frequencies of side
effects among the heaviest infection intensities,
which had been explained by dying schistosomes
and the release of their products. Therefore, severe
side effects are mainly encountered in the high-
est intensity areas (Cioli and Pica-Mattoccia, 2003;
Polderman et al., 1984; Stelma et al., 1995).
There is another important aspect of the present
study worth discussing. It was carried out among
all inhabitants of 75 randomly selected house-
holds, thus containing the entire age range. Most
previous studies pertaining to the epidemiology
of schistosomiasis focused on a particular age
group, usually school-age children (Howard et al.,
2001). This is explained by the fact that this age
group is at highest risk of acquiring the disease,
which is primarily driven by behavioural and im-
munological factors. Consequently, school-age
children display high prevalences and intensities
of schistosome-infections, and often show lower
cure rates than adults (van Lieshout et al., 1999).
Therefore, care is needed in the interpretation of
cure rates following praziquantel administration
because of this potential age bias. To our knowl-
edge this is the first detailed study evaluating praz-
iquantel efficacy against S. mansoni in an entire
community of Côte d’Ivoire. It complements those
11 studies that were previously carried out in dif-
ferent settings of Africa, and that were included in
a recent meta-analysis for interpretation of praz-
iquantel cure rates (Danso-Appiah and De Vlas,
2002). To this end, our work is an important contri-
bution to the ongoing monitoring of praziquantel
efficacy against different schistosome species in
various endemic areas.
Finally, our findings may raise suspicion about
the possible development of praziquantel toler-
ance or resistance, and this is the subject of cur-
rent analyses. Although laboratory experiments
showed that the degree of praziquantel resistance
exhibited by drug-insusceptible isolates is rela-
tively low, and may not be clinically relevant,
failure to monitor these developments may have
serious consequences in the longer term (Doenhoff
et al., 2002). With the launch of new control ini-
tiatives that focus on large-scale administration
of praziquantel in countries of sub-Saharan Africa
(Fenwick et al., 2003), monitoring drug efficacy
over time must become an integral part of control
programme evaluation in general, and the surveil-
lance of praziquantel resistance development in
particular.
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